Stay updated on Study of Efanesoctocog Alfa in Severe Hemophilia A Clinical Trial

Sign up to get notified when there's something new on the Study of Efanesoctocog Alfa in Severe Hemophilia A Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Study of Efanesoctocog Alfa in Severe Hemophilia A Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:24:42.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the efficacy evaluation of BIVV001 as a prophylaxis treatment in patients with severe Hemophilia A in a Phase 3 clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:29.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying age, health conditions, and prior treatments required for inclusion in the study. Previously, this section had no information provided.
    Difference
    25%
    Check dated 2024-05-22T21:36:58.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:39:30.000Z thumbnail image

Stay in the know with updates to Study of Efanesoctocog Alfa in Severe Hemophilia A Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Study of Efanesoctocog Alfa in Severe Hemophilia A Clinical Trial page.